Phio Pharmaceuticals
PHIO
5 hedge funds and large institutions have $758K invested in Phio Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
67% more funds holding
Funds holding: 3 → 5 (+2)
0% more ownership
Funds ownership: 0% → 0% (+0%)
37% less capital invested
Capital invested by funds: $1.19M → $758K (-$436K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$547K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$313K |
| 3 |
Goldman Sachs
New York
|
+$78.2K |
| 4 |
Renaissance Technologies
New York
|
+$78.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$78.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$585K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$16K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $284K | +$547K | +7 | New |
|
|
2
Renaissance Technologies
New York
| $164K | +$78.2K | +1 | +33% |
|
|
3
Hudson Bay Capital Management
Stamford,
Connecticut
| $153K | +$313K | +4 | New |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $66K | +$78.2K | +1 | +100% |
|
|
5
Goldman Sachs
New York
| $41K | +$78.2K | +1 | New |
|
|
VKH
6
Virtu KCG Holdings
New York
| $20K | – | – | – |
|
7
Geode Capital Management
Boston,
Massachusetts
| $19K | – | – | – |
|
|
BIT
8
BlackRock Institutional Trust
San Francisco,
California
| $8K | – | – | – |
|
|
BFA
9
BlackRock Fund Advisors
San Francisco,
California
| $2K | – | – | – |
|
10
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
BC
11
Broadfin Capital
New York
| – | -$585K | -5 | Closed |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$22K | – | – |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| – | -$1K | – | – |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$16K | – | – |
|
PHIO Hedge Fund Activity: Q4 2016 in Review
5 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2016, worth a combined $758K — down 37% from $1.19M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PHIO positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $547K. The largest seller was Broadfin Capital, exiting entirely with an estimated $585K sold.
- 5 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2016, up from 3 in Q3 2016.
- Funds reported $758K of Phio Pharmaceuticals stock for Q4 2016, down 37% quarter-over-quarter.
- 3 funds opened new Phio Pharmaceuticals positions in Q4 2016 and 1 closed out, a net change of +2 holders.
- The largest Phio Pharmaceuticals buyer in Q4 2016 was Sabby Management, an estimated $547K added.
- The largest Phio Pharmaceuticals seller in Q4 2016 was Broadfin Capital, an estimated $585K sold.
Based on aggregated 13F filings for Q4 2016.